# A Study of ALT-801 in Patients With Bacillus Calmette-Guerin (BCG) Failure Non-Muscle Invasive Bladder Cancer

> **NCT01625260** · PHASE1,PHASE2 · TERMINATED · sponsor: **Altor BioScience** · enrollment: 12 (actual)

## Conditions studied

- Non-muscle Invasive Bladder Cancer

## Interventions

- **BIOLOGICAL:** ALT-801
- **DRUG:** Gemcitabine

## Key facts

- **NCT ID:** NCT01625260
- **Lead sponsor:** Altor BioScience
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-03-30
- **Primary completion:** 2018-03-08
- **Final completion:** 2018-03-08
- **Target enrollment:** 12 (ACTUAL)
- **Why stopped:** The study was terminated early due to low enrollment.
- **Last updated:** 2024-07-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01625260

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01625260, "A Study of ALT-801 in Patients With Bacillus Calmette-Guerin (BCG) Failure Non-Muscle Invasive Bladder Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01625260. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*